A nontargeted study of muscle proteome in severely obese women with androgen excess compared with severely obese men and nonhyperandrogenic women

Maria Insenser*, Rafael Montes-Nieto*, M Ángeles Martínez-García and Héctor F Escobar-Morreale

Diabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology and Nutrition, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Carretera de Colmenar km 9,1, E-28034 Madrid, Spain

*(M Insenser and R Montes-Nieto contributed equally to this work)

Abstract

Objective: Androgen excess in women is frequently associated with muscle insulin resistance, especially in obese women with polycystic ovary syndrome. However, whether this is a primary event or the result of indirect mechanisms is currently debated.

Design: This is an observational study.

Methods: We obtained skeletal muscle biopsies during bariatric surgery from severely obese men (n = 6) and women with (n = 5) or without (n = 5) androgen excess. We used two-dimensional differential gel electrophoresis and matrix-assisted laser desorption/ionization-time-of-flight/time-of-flight mass spectrometry to identify muscle proteins showing differences in abundance between the groups of obese subjects.

Results: Women with hyperandrogenism presented the lowest abundances of glycogen phosphorylase, pyruvate kinase, β-enolase, glycerol-3-phosphate dehydrogenase, creatine kinase M-type, and desmin, whereas the abundances of these molecules were similar in control women and men.

Conclusion: According to our nontargeted proteomic approach, women with hyperandrogenism show a specific alteration of the skeletal muscle proteome that could contribute to their insulin resistance. Because men do not show similar results, this alteration does not appear to be the direct effect on muscle of androgen excess, but rather the consequence of indirect mechanisms that merit further studies.

Introduction

The influence of androgens on intermediary metabolism is heavily sex-dependent because both androgen excess in women and androgen deficiency in men facilitate abdominal adiposity, insulin resistance, and related metabolic disorders (1). Moreover, obesity-associated gonadal dysfunction consists of hyperandrogenism in women (2) but hypogonadism in men (3).

As the skeletal muscle is the major site of insulin-stimulated glucose disposal, this tissue becomes a key to understand the effects of androgens on glucose metabolism and insulin resistance. However, not all effects of androgens on muscle are related to glucose metabolism. The skeletal muscle transcription of several genes related to cytoskeleton, cellular matrix, protein synthesis, or cell
proliferation is influenced by the balance of sex hormones in healthy men and women (4). Furthermore, skeletal muscle functions as a peripheral endocrine organ by releasing signaling molecules termed myokines, which are implicated in the regulation of several physiological and metabolic pathways (5, 6) contributing to energy homeostasis.

Nevertheless, changes in muscle metabolism may be explained not only by a direct effect of androgens but also by indirect effects mediated by other organs such as adipose tissue that under influence by androgens (7), may release signaling molecules that influence muscle metabolism. The interplay between adipose tissue and muscle dysfunction appears to play a central role in the development of metabolic disorders in situations that favor the accumulation of dysfunctional adipose tissue (abdominal adiposity or obesity), and/or decreased muscle mass (age- or sedentarism-associated sarcopenia) (1).

Since the proteome – the set of proteins present in a tissue – is the result of gene expression and epigenetic influences, the study of protein abundance in muscle may provide new insights into the molecular processes that lead to metabolic dysfunction in situations where the concentrations of circulating androgens are altered, an issue that has not been addressed in previous proteomic studies of muscle in insulin resistance-related disorders (8, 9, 10).

Hence, we aimed to identify differences in the skeletal muscle proteome using biopsies from severely obese control women, women with hyperandrogenism, and men.

Patients and methods

Subjects

We obtained skeletal muscle samples from 16 severely obese patients (including five women with hyperandrogenism and five women showing no evidence of hyperandrogenism or reproductive dysfunction, and six reproductively healthy men) during bariatric surgery. Biopsies were obtained from *musculus rectus abdominis*, which is a typical skeletal muscle with a fiber type distribution similar, for example, to *m. rectus femoris* muscle (11). The subjects selected had similar mean BMI and age. Clinical, hormonal, and biochemical parameters were determined in the fasting state as described earlier (12, 13) and are summarized in Table 1. Fasting glucose and insulin were used for homeostasis model assessment of insulin resistance (HOMA-IR) (14).

All women in the hyperandrogenic group had hyperandrogenemia (serum total testosterone ≥2.3 nmol/l and/or calculated free testosterone ≥35 pmol/l). Four of the women in this group had also menstrual dysfunction.

Table 1 Clinical, metabolic, and hormonal variables of severely obese subjects from whom skeletal muscle biopsies were obtained during bariatric surgery for proteomic studies. Data are presented as mean ± s.d. Data were submitted to one-way ANOVA followed by the least significant difference post hoc test.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control women (n = 5)</th>
<th>Women with hyperandrogenism (n = 5)</th>
<th>Men (n = 6)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>36 ± 7</td>
<td>33 ± 5</td>
<td>37 ± 7</td>
<td>0.591</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>139 ± 8</td>
<td>137 ± 15</td>
<td>148 ± 19</td>
<td>0.468</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>55 ± 3</td>
<td>52 ± 5</td>
<td>50 ± 6</td>
<td>0.177</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>0.78 ± 0.10</td>
<td>0.86 ± 0.10</td>
<td>1.04 ± 0.06*</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hirsutism score</td>
<td>1 ± 1</td>
<td>10 ± 8*</td>
<td>NA</td>
<td>0.034</td>
</tr>
<tr>
<td>Total testosterone (nmol/l)</td>
<td>1.9 ± 0.7</td>
<td>2.7 ± 1.0</td>
<td>12.8 ± 2.2**</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Free testosterone (pmol/l)</td>
<td>35 ± 10</td>
<td>62 ± 24*</td>
<td>340 ± 55**</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SHBG (nmol/l)</td>
<td>34 ± 10</td>
<td>22 ± 14</td>
<td>19 ± 8</td>
<td>0.089</td>
</tr>
<tr>
<td>DHEAS (µmol/l)</td>
<td>3.0 ± 1.7</td>
<td>6.3 ± 1.0</td>
<td>4.4 ± 2.9</td>
<td>0.095</td>
</tr>
<tr>
<td>Androstenedione (nmol/l)</td>
<td>8.4 ± 1.7</td>
<td>12.9 ± 5.6</td>
<td>9.0 ± 3.5</td>
<td>0.261</td>
</tr>
<tr>
<td>17-hydroxyprogesterone (nmol/l)</td>
<td>2.4 ± 1.2</td>
<td>2.4 ± 0.9</td>
<td>3.6 ± 1.8</td>
<td>0.331</td>
</tr>
<tr>
<td>Alkaline phosphatase (U/l)</td>
<td>83 ± 25</td>
<td>105 ± 26</td>
<td>73 ± 21</td>
<td>0.181</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.5 ± 1.1</td>
<td>5.5 ± 0.5</td>
<td>5.6 ± 1.1</td>
<td>0.130</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/l)</td>
<td>2.4 ± 0.6</td>
<td>3.7 ± 0.6*</td>
<td>3.8 ± 0.8</td>
<td>0.023</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td>1.1 ± 0.3</td>
<td>1.0 ± 0.1</td>
<td>0.9 ± 0.2</td>
<td>0.294</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.8 ± 1.2</td>
<td>2.6 ± 1.1</td>
<td>1.9 ± 0.8</td>
<td>0.398</td>
</tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>5.6 ± 1.9</td>
<td>9.5 ± 5.9</td>
<td>4.9 ± 0.8</td>
<td>0.067</td>
</tr>
<tr>
<td>Fasting insulin (pmol/l)</td>
<td>104 ± 65</td>
<td>146 ± 91</td>
<td>201 ± 87</td>
<td>0.197</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>4.4 ± 4.4</td>
<td>6.9 ± 2.8</td>
<td>6.2 ± 3.0</td>
<td>0.493</td>
</tr>
</tbody>
</table>

HOMA-IR, homoeostasis model assessment of insulin resistance; NA, not applicable; SHBG, sex hormone-binding globulin. *P < 0.05 or less for the difference between women with hyperandrogenism and control women. †P < 0.05 or less for the difference between men and women with hyperandrogenism. ‡P < 0.05 or less for the difference between men and control women.
thereby fulfilling the criteria for polycystic ovary syndrome (PCOS) (15) whereas one woman had hirsutism and hyperandrogenemia but showed regular cycles. Ovarian ultrasound was not conducted. Nonhyperandrogenic control women had no clinical or biochemical evidence of androgen excess and had normal menstrual cycles. Men had no symptoms of gonadal or sexual dysfunction. Written informed consent was obtained from all the participants and the study was approved by the local ethics committee.

Sample preparation and protein labeling
Skeletal muscle samples were obtained during bariatric surgery after a 12-h overnight fast. Samples were washed immediately in PBS and stored at −80 °C until analysis. Proteins were extracted using a Polytron PT-1200C homogenizer with lysis buffer (8.4 mol/l urea, 2.4 mol/l thiourea, 50 g/l 3-((3 cholamidopropyl)dimethylammonio)-1-propanesulfonate, 50 mmol/l dithiothreitol) (16, 17). Homogenized tissues were shaken for 1 h at room temperature and centrifuged at 20 000 × g at 4 °C for 15 min. Interfering elements were removed using 2D Clean-Up Kit (GE Healthcare, Chalfont St Giles, UK), and proteins were resuspended in rehydration buffer (7 mol/l urea, 2 mol/l thiourea, 40 g/l 3-((3 cholamidopropyl)dimethylammonio)-1-propanesulfonate, and 30 mmol/l Tris(hydroxymethyl)aminomethane hydrochloride pH 8.5). Protein concentrations were determined using RD/DC protein assay (Bio-Rad Laboratories). To evaluate the reproducibility of the extraction, all the samples were separated with 12% SDS–PAGE, 4 μg protein per lane, and silver stained (18).

Solubilized proteins (50 μg) were minimally labeled with 400 pmol of either Cy3 or Cy5 fluorescent dye. Protein extracts from individual participants of each group were alternately labeled with Cy3 or Cy5 dyes (to exclude labeling bias). A pool (mixture of equal protein amount of all samples) was labeled with Cy2 dye to serve as an internal standard for normalization in quantitative comparisons. After 30 min of incubation on ice in the dark, the reaction was stopped by incubation with 1 μl 10 mM lysine for 10 min.

Two-dimensional difference in gel electrophoresis, image analysis, and protein identification
Samples were applied by rehybridation in immobilized pH gradient (IPG) strips (24 cm, pH 4–7, linear) and subjected to isoelectrofocusing in an IPGphor isoelectric focusing (IEF) system (GE Healthcare, Freiburg, Germany). Strips were transferred to the top of an SDS–PAGE gel and cast on an Ettan DALTsix electrophoresis unit (GE Healthcare). Digital images of gels were acquired using Typhoon 9400 (GE Healthcare), cropped with ImageQuant (GE Healthcare) and analyzed with DeCyder 2D 7.0. (GE Healthcare). Total protein was detected by poststaining of the gels with Coomassie dye (Bio-Rad Laboratories) or silver. Matrix assisted laser desorption ionization-time-of-flight/time-of-flight (MALDI-TOF/TOF) mass spectrometry (MS) analyses for selected spots were performed using a 4800 proteomics analyzer (Applied Biosystems, MDS Sciex, Toronto, Canada).

Detailed information of proteomic techniques, randomization, and combination of samples and MS analysis of protein spots is included in the minimum information about proteomics experiment (MIAPE) document (Supplementary Table 1, see section on supplementary data given at the end of this article).

Experimental design, data analysis and spot selection
For two-dimensional difference in gel electrophoresis (2D-DIGE) experiments, DeCyder’s differential in gel analysis (DIA) module was used for intra-gel co-detection of samples and internal standard protein spots, allowing the detection of an average of 750 protein spots on each image with a 7.6% coefficient of variation. Artifactual spots were filtered and removed.

In the first experiment we quantified the technical variation of the 2D-DIGE technique when using muscle tissue samples. We analyzed pools of all the samples of each group (control women, women with hyperandrogenism, and men) separately in three gels. The first gel served to compare the pooled samples of control women labeled with Cy3 or Cy5, the second included the pooled samples of women with hyperandrogenism labeled with Cy3 or Cy5, and the third compared the pool of samples from men labeled with Cy3 or Cy5. A mix of the three pools was labeled with Cy2 and was used as internal standard to normalize the results. The comparison among the pools labeled with Cy3 and Cy5 using the DIA module gave an estimation of the experimental variability of the 2D-DIGE procedure for each subject subgroup. The thresholds for the fold-differences in protein abundance warranting with 95% confidence that a difference between the groups being compared did not result from experimental variation were 1.4-fold for control women, 1.5-fold for women with hyperandrogenism and 1.3-fold for men. Therefore, we selected a 1.4-fold difference as the cut-off that
excluded experimental variability when comparing muscle in further experiments.

In the second experiment we evaluated the differences in protein abundance in muscle biopsies from control women, women with hyperandrogenism and men. Half of the samples of each group were labeled with Cy3 and the other half were labeled with Cy5 to avoid biases in labeling efficiency. A pool of all the samples labeled with Cy2 served as internal standard for normalization.

The 24 images from the eight gels were submitted to the biological variation analysis (BVA) module. Based on spot volumes, BVA performed an inter-gel matching that allowed a further comparative cross-gel statistical analysis to detect spots showing different abundance in the groups. The differences between the abundances from two samples are reported as ratios. An average of 310 spots was matched, and their abundances were normalized and quantified. Only spots present in at least 80% of the gel images were submitted for further analyses. Finally, spot matching and data quality were verified manually to exclude artifacts and to avoid false positives.

We decided against applying a priori statistical correction techniques such as q-values to estimate the rate of false discovery at a given value of P, because this approach, aiming to decrease the probability of false discoveries (type 1 errors), would at the same time increase the probability of missing true results (type 2 errors). The latter is a particularly important concern for our study because the number of proteins presenting with differences in abundance with our proteomic untargeted discovery approach is usually small. Instead, we focused on reporting only differences that we were sure did not result from the technical variability of our technique. Hence, we submitted for MS identification only spots showing differences in protein abundance that were not only statistically significant at α = 0.05 level but were also ≥ 1.4-fold in magnitude, thereby excluding any technical variation as their possible cause.

Gene expression analysis

Muscle samples were washed in PBS and immediately stored at −80 °C until submitted for ribonucleic acid (RNA) extraction. Total RNA was isolated from 25 mg of muscle tissue with an RNaseasy Fibrous Tissue Mini Kit according to manufacturer’s guidelines (Qiagen). The concentration and quality of the extracted RNA were assessed by measuring the 260/280 and 260/230 absorbance ratios in a NanoDrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA).

First-strand cDNA was synthesized using equal amounts of total RNA with SuperScript Vilo MasterMix (Invitrogen, Life Technologies) following manufacturer’s instructions. Due to the limited quantity of samples a TaqMan PreAmp Master Mix Kit (Applied Biosystems) was used to increase the amount of specific cDNA targets as described (19). Prevalidated TaqMan Gene Expression assays were used for the relative quantification of PKM (Assay ID: Hs00761782_s1), PYGM (Hs00989942_m1), ENO3 (Hs01093275_m1), GPD1 (Hs01100039_m1), CKM (Hs00176490_m1), and DES (Hs00157258_m1), in a StepOne Plus Real-Time PCR instrument using the StepOne Software v2.1 (Applied Biosystems). Cyclophilin A (PPIA; 4333763F) was used as an endogenous control to normalize target gene expression in each sample (20). A threshold cycle (Ct) was obtained for each amplification curve, and a ΔCt value was first calculated by subtracting the Ct value for cyclophilin A from the Ct value of the specific transcript. Data were expressed as arbitrary units of expression (log2 ΔCt). All samples were performed in triplicate, and negative controls were included in all the reactions.

Western blot analyses

1D and 2D SDS–PAGE western blot analysis was performed using standard techniques and equipment (Bio-Rad Laboratories). In 1D SDS–PAGE western blot analysis 20 μg of skeletal muscle proteins were loaded in 10% polyacrylamide gel. In 2D SDS–PAGE western blot analysis 100 μg of skeletal muscle proteins were separated on 7-cm linear IPG strips pH 4–7 by IEF prior to seal on top of 10% polyacrylamide gel. In 2D SDS–PAGE western blot analysis proteins from both 1D and 2D gels were separated at 150 V for 50 min until the front of the bromophenol blue dye reached the bottom of the gels and were transferred to nitrocellulose membranes (100 mA, 1 h). Membranes were blocked in Tris-buffered saline containing 5% dry non-fat milk for 1 h. Immunoblotting was performed with 1:4000 rabbit polyclonal pyruvate kinase antibody (anti-PKM2 ab137791; Abcam, Cambridge, UK), 1:170 mouse monoclonal glycogen phosphorylase antibody (anti-PPM ab88078), 1:2000 mouse monoclonal desmin antibody (anti-desmin ab6322), 1:2000 rabbit polyclonal gliceraldehyde-3-phosphate dehydrogenase antibody (anti-GPD1 ab153902), 1:4000 mouse monoclonal creatine kinase antibody (anti-CMK ab54637), and 1:12 000 rabbit polyclonal β-enolase antibody (anti-ENO3 ab126259). 1:4000 rabbit polyclonal cytochrome c oxidase subunit four antibody (anti-COXIV ab16056) was utilized as the

www.eje-online.org
loading control in 1D gels and 1:1000 rabbit polyclonal actin (anti-actin ab52218) in 2D gels. Detection was performed with secondary antibodies conjugated to IRDye 800 CW or IRDye 680 RD and densitometric analysis used the Odyssey Infrared Imaging System V.3.0 (LI-COR; Biosciences, Lincoln, NE, USA).

Statistical analysis
Data are expressed as mean ± S.D. unless otherwise stated. After testing the normal distribution of the continuous variables by the Kolmogorov–Smirnov test, we applied logarithmic transformation as needed to ensure normality of skewed variables. Data from control women, women with hyperandrogenism and men were compared by one-way ANOVA followed by post hoc tests as described. Discontinuous variables were compared by χ² test.

The relationships among the proteins identified here, free testosterone and HOMA-IR were analyzed using Spearman’s correlation. We used PASW Statistics 18 (SPSS, Chicago, IL, USA) for analyses. P<0.05 was considered statistically significant.

Results
Clinical, biochemical, and hormonal variables of the subjects included in the study
The variables included in the study are summarized in Table 1. As expected from the design, no differences were found in the age and BMI among the groups. Rates of metabolic complications (hypertension, dyslipidemia, or diabetes) were similar in these groups (3/5 in control women, 3/5 in women with hyperandrogenism, and 3/6 in men; χ²=0.152, P=0.927). Women with hyperandrogenism showed higher hirsutism scores compared with control women. Total and free testosterone concentrations and waist-to-hip ratio were higher, whereas sex hormone-binding globulin (SHBG) concentration was lower, in men compared with control women. Hyperandrogenic women showed values that were in-between those of control women and men, including higher free testosterone concentrations when compared with control women. Fasting glucose and insulin concentrations and HOMA-IR were not statistically different between the groups, however control women showed the lowest surrogate indexes of insulin resistance of all groups, but did not reach statistical significance possibly because of the small sample size of the groups compared here. No differences were observed in lipid profiles with the exception of LDL-cholesterol concentrations which was lower in control women compared to men and women with hyperandrogenism.

Proteome analysis of skeletal muscle samples
We found differences in the protein abundance of seven spots. The logarithms of the standardized protein abundance generated by DeCyder were submitted to one-way ANOVA followed by Bonferroni correction in order to identify the individual groups causing the differences.

Excision, in-gel digestion and MALDI-TOF/TOF analysis of these spots allowed us the identification of the proteins present in six of the seven spots (four were identified matching their peptide mass fingerprint in Mascot database and two were identified using tandem mass spectrometry). The seventh spot could not be identified, probably because of the low amount of protein present in the gels (Fig. 1). Detailed information of the identification process of the six spots is summarized in Table 2, including accession numbers, theoretical molecular weight, isoelectric point values, DeCyder software, and parameters of the identification method, and results of statistical analysis.

Women with hyperandrogenism showed the lowest abundance of the six proteins identified (Table 2 and Fig. 2).

[Figure 1]
Representative 2D-DIGE map of skeletal muscle protein extracts including the pick locations of the proteins identified in this study.
The abundance of pyruvate kinase was lower in hyperandrogenic women compared with control women and men, whereas their abundance of glycogen phosphorylase was lower compared with control women, with men showing intermediate values that were not different compared with both groups of women. The abundances of β-enolase, glycerol-3-phosphate dehydrogenase, creatine kinase M-type, and desmin were lower in hyperandrogenic women compared with men, with control women presenting with intermediate abundances that were not different compared with the other groups. We also analyzed possible sex-dependent differences in protein abundance, considering as a whole obese women with or without androgen excess.

β-enolase (P = 0.01), glycerol-3-phosphate dehydrogenase (P = 0.03) and desmin (P = 0.02) were more abundant in men compared with women, whereas no differences were observed in pyruvate kinase, glycogen phosphorylase, and creatine kinase M-type. With the exception of desmin, which is a structural protein, all the proteins identified in our study have catalytic activity and are involved in muscle energy metabolism.

Validation of the differences found in protein abundance

To verify the 2D-DIGE results, we submitted the 16 skeletal muscle samples to gene expression analysis by real-time quantitative PCR and to 1D and 2D SDS–PAGE western blot analyses. We analyzed pyruvate kinase, glycogen phosphorylase, β-enolase, glycerol-3-phosphate dehydrogenase, creatine kinase M-type, and desmin. With the exception of desmin, the lowest gene expression and protein abundance for the molecules identified here were those of hyperandrogenic women, yet the relatively large dispersion of the data precluded that the apparent differences with respect to the values found in control women and men reached statistical significance (Fig. 3).

To avoid this limitation, we aimed to confirm the differences in creatine kinase M-type and β-enolase abundance in each group (Fig. 4). The abundances in two protein species of each protein were compared in control women and in hyperandrogenic women. We identified here those of hyperandrogenic women, yet the apparent large dispersion of the data precluded the apparent differences in the values found in control women and men reached statistical significance (Fig. 3).

Table 2  Proteins showing different abundances in skeletal muscle samples of severely obese control women (CW), women with hyperandrogenism (HW), and men (M) detected by nontargeted 2D-DIGE.

<table>
<thead>
<tr>
<th>Pos</th>
<th>Protein ID</th>
<th>MW/pI</th>
<th>Protein name</th>
<th>Identification method</th>
<th>Statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PMF</td>
<td>ANOVA P value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PMF and MS/MS</td>
<td>Ratio CW/M</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Post hoc P value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ratio CW/HW</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Post hoc P value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ratio M/HW</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Post hoc P value</td>
</tr>
<tr>
<td>440</td>
<td>P14618</td>
<td>58/7.9</td>
<td>Pyruvate kinase isozymes M1/M2</td>
<td>12 23 73</td>
<td>0.010 1.02 1.000 2.37 0.019 2.33 0.019</td>
</tr>
<tr>
<td>526</td>
<td>P17661</td>
<td>53/5.2</td>
<td>Desmin</td>
<td>11 33 74</td>
<td>0.024 1.5 0.632 1.45 0.298 2.18 0.022</td>
</tr>
<tr>
<td>528</td>
<td>P13929</td>
<td>47/7.5</td>
<td>Creatine kinase M-type</td>
<td>7 2 75</td>
<td>0.047 1.22 1.000 1.37 0.350 1.67 0.049</td>
</tr>
<tr>
<td>565</td>
<td>P06732</td>
<td>43/6.7</td>
<td>Glycerol-3-phosphate dehydrogenase</td>
<td>10 37 59</td>
<td>0.045 1.32 0.432 1.22 0.569 1.61 0.045</td>
</tr>
<tr>
<td>722</td>
<td>P21695</td>
<td>38/5.8</td>
<td>Glycogen phosphorylase</td>
<td>29 29 195</td>
<td>0.046 1.33 1.000 2.31 0.049 1.73 0.247</td>
</tr>
</tbody>
</table>

Pos, position numbers correspond to the position of the proteins in the gel image (Fig. 1); MW/pI, theoretical molecular weight (MW) in kDa and theoretical isoelectric point (pI); PMF, peptide mass fingerprinting; NP, number of peptide mass values matched from MASCOT PMF; SC, amino acid sequence coverage for the identified proteins; score, MASCOT MS protein score, obtained from MALDI-TOF/TOF spectra from the top hit and the second one, larger differences indicate a better result; FP, number of fragmented peptide masses by MS/MS; expect, quality of an individual match. It is the number of times in the search we could expect to get a match with this score or higher by chance; ratio CW/M, ratio control women/men obtained from Decyder; ratio CW/HW: ratio control women/hyperandrogenic women obtained from Decyder; and ratio M/HW: ratio men/hyperandrogenic women obtained from Decyder.

The abundance of pyruvate kinase was lower in hyperandrogenic women compared with control women and men, whereas their abundance of glycogen phosphorylase was lower compared with control women, with men showing intermediate values that were not different compared with both groups of women. We also analyzed possible sex-dependent differences in protein abundance, considering as a whole obese women with or without androgen excess. β-enolase (P = 0.02), glycogen phosphorylase, and creatine kinase M-type were more abundant in men compared with women, whereas no differences were observed in pyruvate kinase, glycogen phosphorylase, and creatine kinase M-type. With the exception of desmin, which is a structural protein, all the proteins identified in our study have catalytic activity and are involved in muscle energy metabolism.
Correlations of protein abundance with clinical variables

In order to identify the proteins that might be related with androgen concentrations and insulin resistance we analyzed the correlations of the protein abundances with free testosterone and HOMA-IR. The abundances of pyruvate kinase and glycogen phosphorylase correlated negatively with HOMA-IR \( (\rho = -0.631, \ P=0.016, \ \text{and} \ \rho = -0.535, \ P=0.033 \ \text{respectively}) \), but we did not find correlations between the abundances of any of the proteins identified in the study and free testosterone (data not shown).

Discussion

Our present nontargeted proteomic analysis of the protein content of skeletal muscle indicates that severely obese women with androgen excess present with reduced abundances of several enzymes related to muscle, glycolysis, glycogenolysis, and energy expenditure, suggesting a certain dysregulation of energy metabolism. This abnormality appears to be specific of hyperandrogenic women given that it was not present in similarly obese control women and men, and might be related to the skeletal muscle insulin resistance characteristic of PCOS (21). Since insulin facilitates muscle glycolysis, the decrease in the abundance of glycolytic enzymes is in conceptual agreement with reduced insulin signaling in the muscle of hyperandrogenic obese women. Glycogen phosphorylase catalyzes the rate-limiting step of glyco-
genolysis; pyruvate kinase catalyzes the final, and \( \beta \)-enolase the penultimate, steps of glycolysis; glyceraldehyde-3-phosphate dehydrogenase is responsible for maintaining the redox potential across the inner mitochondrial membrane in glycolysis and also serves as a link between carbohydrate and lipid metabolism by generating glyceraldehyde-3-phosphate; and creatine kinase M-type plays a central role in the muscle energy transduction needed for glycolysis. Moreover, the decreased abundance of desmin – a muscle-specific intermediate filament involved in cytoskeleton structure that may act as a mechanosignal transducer allowing muscle fibers to sense contractile
activity and respond appropriately – has been also found in association with obesity and type 2 diabetes, influencing insulin resistance (22, 23).

However, the dysregulation in muscle energy enzymes of women with hyperandrogenism does not appear to be the direct result of their androgen excess; otherwise we would have found a similar decrease in the abundance of these enzymes in men, but their protein abundances were similar of those of control women and considerably higher than those observed in hyperandrogenic women. In accordance, the abundances of pyruvate kinase and glycogen phosphorylase showed strong negative correlations with HOMA-IR, but not with free testosterone concentrations.

Even though animal models suggested that exposure of cultured rat myotubes to testosterone might promote insulin resistance by facilitating the insulin-stimulated phosphorylation of several molecules involved in insulin signaling (24), human studies using cultured myotubes from patients with PCOS and healthy women have demonstrated that the mechanisms governing insulin resistance in skeletal muscle of PCOS patients \textit{in vivo} are not primarily defective (25) because even the direct administration of testosterone to these myotubes does not influence insulin sensitivity (26). Together with our present proteomic results, these findings suggest that if androgen excess is implicated in the muscular insulin resistance in PCOS, their effects are probably mediated by indirect mechanisms (26).

Our present cross-sectional experimental design does not permit identifying these indirect mechanisms, but we suspect that obesity and abdominal adiposity might be a link between female androgen excess and muscle insulin resistance based on previous studies from our laboratory (27, 28). Obesity is definitely involved in the development of muscle insulin resistance in androgen excess disorders. A recent non-targeted gas chromatography-mass spectrometry metabolomic study indicated that even though central (hepatic) insulin resistance was present in both lean and obese patients with PCOS, the metabolic profiles of lean patients suggest conserved insulin sensitivity in muscle and adipose tissue whereas the opposite occurred in obese patients, in whom whole-body insulin resistance was apparent (27).

Patients with PCOS are characterized by global and abdominal adiposity (28, 29) when compared with healthy women and men: women with PCOS have higher global adiposity and increased amounts of visceral adipose tissue compared with control women, and even though men have higher total amounts of body fat than women, the amounts of body fat relative to total body mass are higher in patients with PCOS than in men because of the much larger lean body mass of the latter (28). Recent targeted and non-targeted studies suggest that not only the distribution of body fat, but also the function of visceral adipose tissue, is altered in women with PCOS to the extent of resembling that of men and not that of healthy women (7, 19).
In our present small series of severely obese patients the waist-to-hip ratio of women with hyperandrogenism was higher compared to control women, indicating abdominal adiposity. We might speculate if the abdominal adiposity characteristic of hyperandrogenic women, possibly through the dysfunctional secretion of adipokines and other mediators, could influence muscle metabolism reducing the expression and protein abundance of enzymes involved in energy metabolism, leading to the abovementioned muscle insulin resistance. On the contrary, obese healthy men could be protected against the deleterious effects of abdominal adiposity on muscle function because of their much larger muscle mass (1). To this regards, the abovementioned studies in the rat suggested interaction between testosterone and insulin on muscle insulin signaling consisting in low-dose testosterone – leading to mildly increased androgen levels such as might happen in women with functional hyperandrogenism – resulted into altered insulin signaling in female cultured myotubes, but higher testosterone doses – leading to androgen levels similar to that of male animals – ameliorated such negative effects (4). This finding may suggest the possibility of sexual dimorphism in the effects of androgens on muscle insulin signaling, and might contribute to explain why men maintain muscle insulin sensitivity despite very high testosterone concentrations and develop insulin resistance when such concentrations are decreased. The study of the proteomic profile of muscle samples from obese men with androgen deficiency might have shed light into this controversial issue yet, unfortunately, we had no access to these samples for the present study.

Even though the use of 2D-DIGE techniques in our study allowed an accurate quantification of changes in protein abundance that might result from posttranslational modifications, alternative transcription start sites, or alternative splice variants, this technique is not free of limitations such as problematic identification of proteins showing very low abundance, extreme isoelectric point and/or low molecular weight, or very hydrophobic proteins. Moreover, our study may have been underpowered to detect differences in the abundance of other proteins. Hence, with our experimental design we cannot exclude a wider alteration of muscle proteome in obese women with hyperandrogenism.

In conclusion, obese hyperandrogenic women present with reduced abundance of enzymes and structural proteins involved in energy metabolism that might contribute to skeletal insulin resistance. However, these findings do not appear to be the direct consequence of androgen excess because men do not show any of these changes in protein abundance. Our present results may serve as the basis for future studies addressing the indirect mechanisms that induce specific muscle proteome abnormalities in women with hyperandrogenism.

**Supplementary data**
This is linked to the online version of the paper at [http://dx.doi.org/10.1530/EJE-15-0912](http://dx.doi.org/10.1530/EJE-15-0912).

**Declaration of interest**
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**
Supported by grants PI1100357 and PI1501686 from Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness. Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas is also an initiative of Instituto de Salud Carlos III. Supported in part by Fondo Europeo de Desarrollo Regional FEDER (European Union).

**Author contribution statement**
M Insenser, R Montes-Nieto, and M Á Martínez-García. researched data, drafted the manuscript, and contributed critically to discussion. H F Escobar-Morreale designed the study, researched data, analyzed the results and wrote the final version of the manuscript. All authors approved the decision to submit the manuscript and take public responsibility for its whole content.

**References**


12 Escobar-Morreale HF, Lasuncion MA & Sancho J. Treatment of hirsutism with ethanol estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertility and Sterility 2000 74 816–819. (doi:10.1001/s0015-0282(00)00718-4)


